Full Press Release Details
PHARMACEUTICALS COMMENCES PHASE 2A TRIALS OF ITS
INSULIN CAPSULE ON TYPE 1 DIABETICS
assess the safety and efficacy of ORMD 0801,oral insulin capsule, on Type 1
Israel - September 24, 2008 - Oramed Pharmaceuticals, Inc. (OTCBB: ORMP.OB;
developer of oral delivery systems, announced today that it has commenced Phase
2A studies of ORMD 0801, its oral insulin capsule, on Type 1 diabetics at the
Hadassah University Medical Center in Jerusalem, Israel.
Phase 2A trial is focused on assessing the safety and efficacy of its oral
insulin capsule on nine Type 1 diabetes patients.
of this clinical trial on Type 1 Diabetic patients follows completion by the
company of similar trials on Type 2 diabetic patients, which demonstrated that
ORMD 0801 had a good safety profile and was effective in lowering blood glucose
levels without any serious adverse events.
commencement of trials of our oral insulin capsule on Type 1 diabetics signals
another major step forward for our company in the treatment of diabetes," said
Nadav Kidron, Oramed CEO. "The successful results from our trials on Type 2
diabetics were very encouraging and we hope to achieve similar results from
Oramed Pharmaceuticals
Pharmaceuticals is a technology pioneer in the field of oral delivery solutions
for drugs and vaccines presently delivered via injection. Oramed is seeking
to revolutionize the treatment of diabetes through its patented flagship
product, an orally ingestible insulin capsule currently in Phase 2 clinical
trials. Established in 2006, Oramed's technology is based on over 25 years of
research by top research scientists at Jerusalem's Hadassah Medical Center. The
Company's corporate and R&D headquarters are based in Jerusalem.
more information, please visit www.oramed.com
the statements contained in this press release are forward-looking statements
which involve known and unknown risks, uncertainties and other factors which
cause the actual results, performance or achievements of the company, or
industry results, to be materially different from any future results,
performance or achievements expressed or implied by such forward looking
statements, including the risks and uncertainties related to the progress,
timing, cost, and results of clinical trials and product development programs;
difficulties or delays in obtaining regulatory approval for our product
candidates; competition from other pharmaceutical or biotechnology companies;
and the company's ability to obtain additional funding required to conduct its
research, development and commercialization activities. Please refer to the
company's filings with the Securities and Exchange Commission for a
list of risk factors that could cause actual results, performance or
achievements of the company to differ materially from those expressed or implied
in such forward looking statements. The company undertakes no obligation to
update or revise any forward-looking statements.
and Investor Relation Contacts:
Finn Israel for Oramed